George G Holz, PhD

George G Holz, PhD
Appointed 12/03/07
4310 Institute For Human Performance
505 Irving Ave.
Syracuse, NY 13210

315 464-9841

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Medicine: Endocrinology, Diabetes and Metabolism

Research Programs and Affiliations

  • Biomedical Sciences Program
  • Cancer Research Institute
  • Medicine
  • Research Pillars

Web Resources

Education & Fellowships

  • PhD: University of Illinois College of Medicine at Chicago, 1984, Pharmacology
  • BS: Cornell University, 1975, Physiology

Previous Appointments

  • Harvard Medical School, 1990–1998
  • New York University School of Medicine, 1998–2007
  • Tufts University School of Medicine, 1984–1990

Research Interests

  • Drug development for the treatment of type 2 diabetes mellitus.

Web Resources

Publications

Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

Our laboratory is performing studies of the "Incretin Mimetics", a newly recognized class of blood glucose-lowering agents that stimulate pancreatic insulin secretion, and which are likely to be the next line of defense for the treatment of type 2 diabetes mellitus. Incretin mimetics mimic the action of GLP-1 (glucagon-like peptide-1), a naturally-occurring incretin hormone secreted by L-cells of the intestine, and which when administered to type 2 diabetic subjects, lowers concentrations of blood glucose.

Why are GLP-1 and the incretin mimetics of special interest? Perhaps most remarkable is the finding that the immediate blood glucose-lowering action of these compounds in type 2 diabetic subjects is self-terminating once normoglycemia is achieved. Thus, unlike administered insulin, there exists a natural safeguard such that these agents are less likely to produce hypoglycemia when they are adminstered for therapeutic purposes. One such incretin mimetic is Amylin Pharmaceutical's Byetta. It is an insulin secretagogue that is structurally-related to GLP-1, but unlike GLP-1 it exhibits an extended duration of action. Understanding how the beneficial "antidiabetogenic" actions of GLP-1 and Byetta are achieved is a primary focus of my research.

Faculty Profile Shortcut: http://www.upstate.edu/faculty/holzg
Eric Wohlford

Eric Wohlford

Eric Wohlford received a 2012 travel award from the American Society of Tropical Medicine and Hygiene and spent two months in Kenya working in the lab of Rosemary Rochford, PhD, professor and chair of Upstate’s Department of Microbiology & Immunology. Eric studied the effects of malaria on B cells (producers of antibodies that fight infection) and Epstein-Barr Virus infection in the region. “Tropical medicine is unique, in that small, focused improvements in patient care make dramatic improvements in the well-being of patients,” he said.

Read More >

Download the MD/PhD 2013-14 Brochure. PDF document